HyperLink
    26 - 27 April 2007, Philadelphia, USA

Remind me about this conference in:
Email Address:    

 

Agenda

 

Day One - April 26

8:00am
Registration
9:00am
 
Trends and Emerging Technologies in Molecular Diagnostics - Part I
Session Chair: Gregory Riggins, Associate Professor, Johns Hopkins University School of Medicine
9:05am
 

Licensing Issues in Molecular Diagnostics
Robert Morrison, Managing Director, Bioinvension
The presentation will provide audience members with a perspective on licensing and intellectual property that is not often discussed at such conferences. Intellectual property issues are critical for eventual applications of the technology.

9:35am
 

A Simple Algorithm for Assessing Overall and Specific Impact of Diagnostic-type Tests on Medicines Development and Marketing
Eddie Blair, Managing Director, Integrated Medicines
Determining the added value that a diagnostic test brings to pharmaceutical product development is key to integrating one or more partners involved. We will describe how such valuations are affected by a number of parameters that then determine the optimal business relationships.

10:05am
Coffee & networking in exhibition hall
10:50am
 

Point of Care Diagnostic Landscape - A Role for Molecular Diagnostics?
Pamela Foreman, Principal, Foreman Solutions Biotechnology Consulting

11:20am
 
 

Beyond Amplification: Use of Direct Linear Analysis to Diagnose Human Infectious Diseases
Carolyn Conant, Staff Scientist, U.S. Genomics

11:50am
 
Trends and Emerging Technologies in Molecular Diagnostics - Part II
Session Chair: K.K. Jain, CEO, Jain Pharmabiotech
11:55am
 

Comparison of Methods to Discover/Validate Methylated DNA Biomarkers and Test Patients--Bisulfite vs. Enzymatic Preparations for Microarray and PCR Assays
John Langmore, VP Commercial Development, Rubicon Genomics
DNA methylation is important in cancer and other diseases. There are two major approaches for discovery and validation of new methylated DNA biomarkers, and for patient testing. The bisulfite conversion and enzymatic methods are evaluated theoretically and experimentally.

12:25pm

Lunch & poster viewing

1:55pm
 

EGFR Mutation Detection and SNP Genotyping in 30 minutes; A novel, new Molecular Diagnostic Technology
Paul Cizdziel, Senior Scientist, RIKEN Yokohama Institute
An isothermal SMart Amplification Process (SMAP) with a unique background suppression technology enables precise, low-cost, simple, and rapid (30 min) detection of SNPs and mutations directly from lysed blood or tumor cells, suitable for point-of-care molecular diagnostics.

2:25pm
 

Nanoliter High Throughput Quantitative PCR
Sergey Ilyin, Bioinformatics Group Leader, Johnson & Johnson Pharmaceutical Research & Development

2:55pm 
Coffee & networking in exhibition hall
3:40pm

Use of Microtranponders in Fluidics-based DNA Assays
Wlodek Mandecki, President, PharmaSeq
PharmaSeq provides ultra-small electronic chips, microtransponders, and a fluidics-based analytical instrument to perform complex bioassays. The major benefits are: very large number of IDs, fluidic readout, scalability and traceability of each chip.

4:10pm

4-plex Three-Locus Real-time PCR Assays for Methicillin-Resistant Staphylococcus aureus (MRSA)
Yosef Paitan, Scientific Advisor, Syntezza
Syntezza has developed a premixed, room temperature, stable, real-time PCR assay to detect and accurately differentiate MRSA from other staphylococci.

4:40pm

Production and QC of Oligonucleotides for use in Clinical Diagnostic Applications
Trey Martin, COO, Integrated DNA Technologies

5:10pm
Drinks reception in exhibition hall

Back to top

Day Two - April 27

9:00am
PGx and Personalized Medicine - Part I
Session Chair: Pamela Foreman, Principal, Foreman Solution Biotechnology Consulting
9:05am

Keynote Address - Innovative Molecular Diagnostics for Personalized Medicine
K.K. Jain, CEO, Jain Pharmabiotech 

9:50am

Forty Seven (47) Protein Biomarkers in Blood Serum for Early Detection, Differential Diagnosis, and Monitoring of Disease Severity of Patients with Neurodegenerative Diseases
Ira Goldknopf, Director of Proteomics, Power3Medical Products, Inc.

10:20am
Coffee & networking in exhibition hall
11:05am

Keynote Address - Distinguishing Adenoma from Carcinoma in Thyroid Cancers
Gregory Riggins, Associate Professor, Johns Hopkins University School of Medicine
Protein markers can be used to help distinguish benign thyroid tumors from thyroid cancer.

11:50am

Development of a Multi-gene Test for the Early Assessment of Susceptibility to Autism
Jorg Hager, CSO, IntegraGen
Developing multi-gene tests for complex diseases has specific challenges in terms of technology, regulations and set-up of clinical trials. Here we discuss the development of a risk assessment test for autism as a case study.

12:20pm     Lunch and poster viewing
1:40pm
PGx and Personalized Medicine - Part II
Session Chair: Ira Goldknopf, Director of Proteomics, Power3Medical Products, Inc.
1:45pm

Multi Center Validation of a New Molecular Diagnostic Assay for Accurate and Rapid Screening of JAK2 V617F Mutation
Fabienne Hermitte, CSO, Ipsogen

2:15pm

Targeted Metabolomics - Use Cases and Visions for Molecular Diagnostics
Klaus Weinberger, CSO, BIOCRATES Life Sciences
Quantitative metabolomics is ideally suited to identify novel biomarkers for complex pathophysiological effects and, therefore, paves the way to a mechanistic understanding and to functional biochemical diagnostics of diseases like diabetes, atherosclerosis or renal insufficiency.

2:45pm 

Close of Conference